SION — Sionna Therapeutics, Inc. Stock Price, Chart & AI Report

Neutral Jan 3, 2026 • 19:35 UTC The Motley Fool • Cory Renauer

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatments, reported positive phase 1 results in June and began phase 2 trials in October, with top-line results expected mid-2026.

SION insider sale cystic fibrosis clinical-stage biotech CFTR protein phase 2 trial OrbiMed Advisors rare disease

Sentiment note

The insider sale is characterized as routine income supplementation rather than a sign of distress, with the seller retaining substantial holdings (3.56M shares). The company shows clinical progress with positive phase 1 results and ongoing phase 2 trials, but remains pre-commercial with significant development risk ahead. The neutral sentiment reflects both positive clinical progress and the inherent uncertainty of clinical-stage biotech development.

Positive Oct 21, 2025 • 11:00 UTC GlobeNewswire Inc. • Sionna Therapeutics

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics initiated a Phase 2a clinical trial evaluating SION-719, a novel NBD1 stabilizer, as an addition to standard cystic fibrosis treatment Trikafta. The trial aims to assess safety, tolerability, and potential improvement in CFTR protein function, with topline data expected in mid-2026.

SION cystic fibrosis clinical trial CFTR protein NBD1 stabilizer Trikafta

Sentiment note

Company is advancing innovative treatment approach, initiating first clinical trial for NBD1 stabilizer, with potential to improve cystic fibrosis treatment outcomes

Positive Aug 27, 2025 • 11:00 UTC GlobeNewswire Inc. • Sionna Therapeutics

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, will participate in two upcoming investor conferences in September 2025, presenting their research on CFTR protein function normalization.

SION cystic fibrosis CFTR protein biopharmaceutical investor conferences

Sentiment note

Company is actively presenting at investor conferences, demonstrating progress in clinical research for cystic fibrosis treatments and potential investor interest

Positive Feb 10, 2025 • 21:03 UTC Benzinga • Globe Newswire

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.

SION Sionna Therapeutics IPO cystic fibrosis CFTR protein

Sentiment note

The company successfully completed an upsized IPO, raising a significant amount of capital to fund its development of novel cystic fibrosis treatments, which indicates a positive outlook for the company's future prospects.